Tenderwize
Zurück zur Suche

Open House Original Discount Contracts 2025-27 - Ribociclib

Techniker Krankenkasse·Hamburg, Germany·Deadline Oct 30, 2027 · 432 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-27 - Ribociclib

70/100

Opportunity Score

PromisingLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

70 / 100

Komplexität

20 / 100

Risikofaktoren

Contract ends automatically at the end of the month in which the patent or market exclusivity for Ribociclib expires. T...

No estimated value or volume is provided; revenue is uncertain and depends on actual prescriptions.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Strong opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Oct 2027
  • Conclude discount contracts for the active ingredient Ribociclib with eligible pharmaceutical entrepreneurs.
  • Ensure pharmacy software update for new discount products by submitting documents before the 3rd of the preceding month.
Vollständige Zusammenfassung anzeigen

Open House procedure by Techniker Krankenkasse (TK) to conclude discount contracts (Rabattverträge) for the active ingredient Ribociclib under §130c SGB V. The process is non-competitive: any eligible pharmaceutical entrepreneur that meets the criteria (valid marketing authorization, being a pharmaceutical entrepreneur within EU/EEA) can join at any time during the contract duration (01.11.2025 – 31.10.2027). No exclusivity is granted. The notice clarifies this is not a public procurement under EU directives; legal recourse is to social courts. No estimated value is provided. Contract termination occurs automatically upon patent expiry. Documents are available online but submission is via email or post (not electronic via the platform).

Risiken

Contract ends automatically at the end of the month in which the patent or market exclusivity for Ribociclib expires. T...

No estimated value or volume is provided; revenue is uncertain and depends on actual prescriptions.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Be a pharmaceutical entrepreneur within the meaning of §4(18) AMG, with a valid marketing authorization (or equivalent right) for Ribociclib.

Eligibility

  • No exclusion grounds analogous to §§123, 124 GWB for the last 3-5 years.

Administrative

  • Submit signed contract documents (including self-declaration on authorization and company – Anlage 4) via email with qualified electronic signature or by post.

Anforderungen können unvollständig sein.

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Open House Original Discount Contracts 2025-27 - Ribociclib

Conclusion of discount contracts for the active ingredient Ribociclib with eligible pharmaceutical entrepreneurs. The contract has a maximum duration of 24 months starting 01.11.2025, ending no later than 31.10.2027. Early termination upon patent expiry.

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

Oct 2025 - Oct 2027

Kategorie

Pharmaceutical products

Vergabedetails

Veröffentlichungsdatum
17 Sep 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
612458-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3